Outcomes after fingolimod to alemtuzumab treatment shift in relapsing–remitting MS patients: a multicentre cohort study

Overview of attention for article published in Journal of Neurology, June 2019

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 3,223 followers.

RT @ingentium_ms: Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting #MSPatients: a multicentre cohort study.…

Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting #MSPatients: a multicentre cohort study. https://t.co/tqdFX6QUtw

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.